BR112022003852A2 - Métodos de preparação de células t para terapia de células t - Google Patents

Métodos de preparação de células t para terapia de células t

Info

Publication number
BR112022003852A2
BR112022003852A2 BR112022003852A BR112022003852A BR112022003852A2 BR 112022003852 A2 BR112022003852 A2 BR 112022003852A2 BR 112022003852 A BR112022003852 A BR 112022003852A BR 112022003852 A BR112022003852 A BR 112022003852A BR 112022003852 A2 BR112022003852 A2 BR 112022003852A2
Authority
BR
Brazil
Prior art keywords
cells
preparing
methods
cell therapy
cell
Prior art date
Application number
BR112022003852A
Other languages
English (en)
Inventor
Chupei Zhang
W Leonard Mark
Charles Pertel Thomas
Yajin Ni
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Publication of BR112022003852A2 publication Critical patent/BR112022003852A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631Chimeric Antigen Receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411Immunoglobulin superfamily
    • A61K39/464412CD19 or B4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998Proteins not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/70Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

métodos de preparação de células t para terapia de células t. são fornecidos neste documento métodos para preparar células t para terapia de células t compreendendo o contato de uma população de células em uma densidade celular predeterminada, com uma concentração de uma nanomatriz anti-cd3/cd28 e a cultura das células produzindo, assim, uma população de células t compreendendo uma porcentagem aumentada de pelo menos um subtipo de célula t. em algumas modalidades, o método aumenta a porcentagem de células t tronco de memória.
BR112022003852A 2019-09-03 2020-09-02 Métodos de preparação de células t para terapia de células t BR112022003852A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962895381P 2019-09-03 2019-09-03
PCT/US2020/049074 WO2021046134A1 (en) 2019-09-03 2020-09-02 Methods of preparing t cells for t cell therapy

Publications (1)

Publication Number Publication Date
BR112022003852A2 true BR112022003852A2 (pt) 2022-05-31

Family

ID=72521739

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003852A BR112022003852A2 (pt) 2019-09-03 2020-09-02 Métodos de preparação de células t para terapia de células t

Country Status (11)

Country Link
US (1) US20210062150A1 (pt)
EP (1) EP4025688A1 (pt)
JP (1) JP2022546537A (pt)
KR (1) KR20220054383A (pt)
CN (1) CN114341348A (pt)
AU (1) AU2020343300A1 (pt)
BR (1) BR112022003852A2 (pt)
CA (1) CA3147441A1 (pt)
IL (1) IL291074A (pt)
MX (1) MX2022002527A (pt)
WO (1) WO2021046134A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113046306B (zh) * 2021-03-12 2022-10-18 广东东阳光药业有限公司 一种多能干细胞的培养方法
EP4321534A1 (en) * 2021-04-08 2024-02-14 Takeda Pharmaceutical Company Limited Method for activating t-cells
EP4363558A1 (en) * 2021-07-01 2024-05-08 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
WO2023232745A1 (en) * 2022-05-30 2023-12-07 Mediterranea Theranostic S.R.L. Anti-idiotype antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
MX347078B (es) 2010-12-09 2017-04-10 Univ Pennsylvania Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
JP6661544B2 (ja) * 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したt細胞の自動生成法

Also Published As

Publication number Publication date
WO2021046134A1 (en) 2021-03-11
US20210062150A1 (en) 2021-03-04
MX2022002527A (es) 2022-04-01
KR20220054383A (ko) 2022-05-02
CN114341348A (zh) 2022-04-12
AU2020343300A1 (en) 2022-03-03
JP2022546537A (ja) 2022-11-04
WO2021046134A9 (en) 2021-10-07
IL291074A (en) 2022-05-01
CA3147441A1 (en) 2021-03-11
EP4025688A1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
BR112022003852A2 (pt) Métodos de preparação de células t para terapia de células t
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
MX2019015021A (es) Metodo de fabricacion de anticuerpos biespecificos, anticuerpos biespecificos y uso terapeutico de dichos anticuerpos.
BR112019000512A2 (pt) anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
TR201900776T4 (tr) Memeli hücre kültürlerinin hasadına ilişkin yöntem.
MX2020013977A (es) Proteínas quiméricas transmembrana y usos de las mismas.
BR112015027996A8 (pt) Organoides compreendendo células renais isoladas e suas utilizações
MX2019012017A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
CY1124672T1 (el) Μεθοδοι αποθηκευσης τραπεζων κυτταρων εξαιρετικα υψηλης πυκνοτητας
MX2021005021A (es) Proceso para producir celulas t geneticamente modificadas.
MX2021011816A (es) Metodos para produccion de celulas car-nk y uso de las mismas.
MX2020005908A (es) Proceso para producir una composicion de celulas t modificadas.
BR112021014645A2 (pt) Método de edição de genes
CO2022007238A2 (es) Terapia de células t del receptor de antígeno quimérico
MX2020009648A (es) Muestreador de lecho fijo y metodos relacionados.
MX2020009907A (es) Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular.
CY1111769T1 (el) Παρασκευη κυτταρων
CL2020000734A1 (es) Expansión y uso de fracciones de células nk ampliadas.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
BR112016028512A8 (pt) método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante
BR112022010179A2 (pt) Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso
BR112021024946A2 (pt) Célula de mamífero, método para produzir uma célula de mamífero implantável, e, uso de uma célula de mamífero
MX2022012062A (es) Receptores de linfocitos t.
AR118369A1 (es) Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도